Logo
x

Search

Subscribe Now

Bavarian Nordic

Bavarian Nordic’s CHIKV VLP Receives EMA’s Accelerated Assessment for Chikungunya

Bavarian Nordic’s CHIKV VLP Receives EMA’s Accelerated Assessment for Chikungunya

  • February 24, 2024
Bavarian Nordic Reports P-III Clinical Trial Results of CHIKV VLP (PXVX0317) for Chikungunya Virus Vaccine in Adults and Adolescents

Bavarian Nordic Reports P-III Clinical Trial Results of CHIKV VLP (PXVX0317) for Chikungunya Virus Vaccine in Adults and Adolescen...

  • August 7, 2023
Bavarian Nordic to Acquire Emergent BioSolutions’ Vivotif, Vaxchora and an Under Developed Chikungunya Vaccine 

Bavarian Nordic to Acquire Emergent BioSolutions’ Vivotif, Vaxchora and an Under Developed Chikungunya Vaccine 

  • February 15, 2023
Bavarian Nordic Reports the First Patient Dosing in P-III (VANIR) Trial for the Treatment of Respiratory Syncytial Virus

Bavarian Nordic Reports the First Patient Dosing in P-III (VANIR) Trial for the Treatment of Respiratory Syncytial Virus

  • April 20, 2022
Bavarian Nordic’s MVA-BN RSV Receives the US FDA’s Breakthrough Therapy Designation for Prevention of Respiratory Syncytial Virus

Bavarian Nordic’s MVA-BN RSV Receives the US FDA’s Breakthrough Therapy Designation for Prevention of Respiratory Syncytial Virus

  • February 14, 2022
Bavarian Nordic Plans to Initiate P-III Trial of Respiratory Syncytial Virus Candidate MVA-BN

Bavarian Nordic Plans to Initiate P-III Trial of Respiratory Syncytial Virus Candidate MVA-BN

  • December 6, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.